Europe Rapid Diagnostic Tests Rdt Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2031 |
 Tamanho do mercado (ano base ) | USD 12.05 Billion |
 Tamanho do mercado ( Ano de previsão) | USD 21.64 Billion |
 CAGR |
% |
| Principais participantes do mercado |
Mercado europeu de testes de diagnóstico rápido (RDT), por tipo de produto (consumíveis e kits, instrumentos e outros), modo (profissional e de venda livre [OTC]), tecnologia (baseada em PCR, ensaios de fluxo, ensaios de fluxo lateral Imunocromatográficos, Ensaio de Aglutinação, Microfluídica , Tecnologia de Substrato e Outros), Modalidade (Teste Baseado em Laboratório e Teste Não Laboratorial), Faixa Etária (Adulto e Pediátrico), Tipo de Teste (Determinação de Confirmação, Teste Sorológico e Sequenciamento Viral), Abordagem (Diagnóstico in vitro e diagnóstico molecular ), amostra (cotonete, sangue, urina, saliva, expetoração e outros), aplicação (testes de doenças infeciosas, monitorização da glicose, testes cardiológicos, testes oncológicos, testes cardiometabólicos, testes de drogas de abuso , testes de gravidez e fertilidade, testes de toxicologia e outros), utilizador final (hospital e clínica, laboratório de diagnóstico, ambiente de cuidados domiciliários, institutos académicos e de investigação e outros), canal de distribuição (concurso direto e venda a retalho) - tendências e previsões do setor para 2031.
Análise e insights de mercado de testes de diagnóstico rápido (RDT) da Europa
O aumento dos testes de diagnóstico rápido para o diagnóstico de doenças infecciosas crónicas, como o vírus da imunodeficiência humana ( VIH ), a malária e outras doenças estão a impulsionar o crescimento do mercado. A falta de profissionais qualificados tem provocado muitos acidentes e os erros durante o diagnóstico deverão desafiar o crescimento do mercado.
A Data Bridge Market Research analisa que o mercado europeu de testes de diagnóstico rápido (RDT) deverá atingir os 21,64 mil milhões de dólares até 2031, contra os 12,05 mil milhões de dólares em 2023, crescendo com um CAGR saudável de 8,2% no período de previsão de 2024 a 2031.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2024 a 2031 |
|
Ano base |
2023 |
|
Anos históricos |
2022 (personalizável para 2016–2021) |
|
Unidades Quantitativas |
Receita em biliões de dólares |
|
Segmentos cobertos |
Tipo de produto (consumíveis e kits, instrumentos e outros), modo (profissional e de venda livre [OTC]), tecnologia (baseada em PCR, ensaios de fluxo, ensaios imunocromatográficos de fluxo lateral, ensaio de aglutinação, microfluídica, tecnologia de substrato , e Outros), Modalidade (Teste Laboratorial e Teste Não Laboratorial), Faixa Etária (Adulto e Pediátrico), Tipo de Teste (Determinação de Confirmação, Teste Sorológico e Sequenciação Viral), Abordagem (Diagnóstico In Vitro e Diagnóstico Molecular), Amostra ( cotonete, sangue, urina, saliva, expetoração e outros), aplicação (testes de doenças infeciosas, monitorização da glicemia, testes cardiológicos, testes oncológicos, testes cardiometabólicos, testes de drogas de abuso, testes de gravidez e fertilidade, testes toxicológicos e Outros) , Utilizador Final (Hospital e Clínica, Laboratório de Diagnóstico, Ambiente de Atendimento Domiciliário, Institutos Académicos e de Investigação e Outros), Canal de Distribuição (Concurso Direto e Venda a Retalho) |
|
Países abrangidos |
Alemanha, França, Reino Unido, Itália, Espanha, Rússia, Turquia, Bélgica, Países Baixos, Suíça e Resto da Europa |
|
Participantes do mercado abrangidos |
Abbott, Danaher, Cellex, Fujirebio, AdvaCare Pharma, ACCESS BIO, Cardinal Health, Bio-Rad Laboratories, Inc., Cepheid, BD, F. Hoffmann-La Roche Ltd, bioMérieux SA, InBios International, Inc, Luminex Corporation, Gnomegen LLC , QIAGEN, Quidel Corporation, , Inc., Sysmex Corporation, Cardinal Health, Siemens Healthcare Gmbh, MEGACOR DIAGNOSTIK, PerkinElmer Inc., Sekisui Diagnostics, PTS Diagnostics, werfen, Nova Biomedical e Trinity Biotech, entre outros |
Definição de mercado
Os testes de diagnóstico rápido são preferidos aos testes de diagnóstico padrão, uma vez que podem melhorar a análise etiológica de infeções em diversas situações (por exemplo, sépsis, infeções do trato respiratório e meningite). A elucidação dos testes de diagnóstico rápido atualmente disponíveis nem sempre é antecipada e, por isso, ainda não podem substituir os testes convencionais. Existem três tipos de testes de diagnóstico rápido. As tiras ou cassetes de teste de imunoensaio rápido são utilizadas para medir a concentração de um produto químico. As tiras de teste são utilizadas com mais frequência para testar o nível de pH de um líquido numa amostra, mas alguns tipos de tiras de teste servem outros fins, como a deteção da presença de um contaminante.
Dinâmica do mercado de testes de diagnóstico rápido (RDT) na Europa
Motoristas
- Aumento da incidência de doenças crónicas
Os fatores impulsionadores responsáveis pelo crescimento do mercado são o aumento da incidência de doenças crónicas, o aumento da população geriátrica, a evolução tecnológica nos testes de diagnóstico rápido e o aumento do lançamento de produtos. No entanto, os fatores que deverão restringir o mercado são o aumento do custo dos diagnósticos rápidos, as recolhas de produtos enfrentadas nos testes de diagnóstico rápido e a falta de sensibilização para a utilização de diagnósticos rápidos. Além disso, as iniciativas estratégicas dos players do mercado e o aumento dos gastos em saúde reforçam o crescimento do mercado.
- Aumento da população geriátrica das doenças infeciosas
A população idosa em todo o mundo enfrenta um risco acrescido de doenças crónicas e malignas devido a uma variedade de factores, incluindo alterações no sistema imunitário, estilo de vida e exposição a factores ambientais ao longo do tempo. A suscetibilidade da população geriátrica a tais desafios de saúde realça a importância de ferramentas de diagnóstico eficazes e eficientes para identificar e gerir estas condições. Um aspeto notável neste contexto é a prevalência de anticorpos inespecíficos nos idosos, tornando a deteção de doenças específicas mais desafiante.
Oportunidade
- Iniciação Estratégica e Lançamentos de Produtos por Participantes no Mercado
O mercado vive uma tendência notável marcada por uma crescente iniciação de novos produtos e lançamentos. Este aumento da inovação sublinha a natureza dinâmica do cenário de diagnóstico, com as empresas a introduzirem ativamente novas soluções para responder às crescentes necessidades de cuidados de saúde. A crescente procura de ferramentas de diagnóstico precisas e rápidas, especialmente no contexto do envelhecimento da população, estimulou o aumento do investimento em investigação e desenvolvimento.
Restrições/Desafios
- Elevado custo associado aos kits de diagnóstico rápido
O aumento do custo do kit de diagnóstico rápido devido à investigação robusta e à eficácia. No entanto, o preço do material utilizado e os desenvolvimentos ocorridos na terapêutica e nos serviços aumentariam o número de unidades de produção e mais mão-de-obra e recursos humanos necessários para diagnosticar e rastrear a viabilidade dos agentes patogénicos.
O custo de desenvolvimento rápido do diagnóstico é dispendioso e requer uma estratégia de aquisição de protocolos adequada. No entanto, as clínicas especializadas e os laboratórios de diagnóstico enfrentam obstáculos na aquisição de dispositivos de teste devido à baixa situação económica, o que limitaria as vendas de kits de teste e seus acessórios.
- Regulamentações rigorosas para aprovação de mercado
São fornecidos regulamentos para todos os aspetos dos testes de diagnóstico rápido, como o diagnóstico in vitro e molecular. Estas regras e regulamentos são necessários para aprovação no mercado para garantir a segurança dos doentes.
A obtenção destas aprovações regulamentares para a formalidade legal pode implicar despesas financeiras significativas, que podem levar meses ou anos a serem concluídas. Se estas limitações não forem conhecidas ou tidas em conta, a probabilidade de sucesso num mercado altamente competitivo poderá ser significativamente exposta por atrasos, o que deverá desafiar o crescimento do mercado.
Desenvolvimentos recentes
- Em maio de 2023, a F. HOFFMANN-LA ROCHE LTD anunciou oficialmente a aquisição da Stratos Genomics. Esta aquisição levou ao desenvolvimento de sequenciação baseada em ADN para utilização em diagnóstico. Isto potenciou o segmento de diagnóstico de saúde da empresa, gerando mais geração de receitas para a empresa
- Em abril de 2023, em julho, o BIOFIRE Respiratory Panel 2.1 plus da bioMérieux SA testa para 23 agentes patogénicos, incluindo a infeção por SARS-CoV-2, responsável por infeções do trato respiratório, está comercialmente disponível para utilização em todo o mundo e ajuda no diagnóstico precoce das infecções respiratórias . Este desenvolvimento ajudou a empresa a gerar mais receitas
Âmbito do mercado de testes rápidos de diagnóstico (RDT) da Europa
O mercado europeu de testes de diagnóstico rápido (RDT) está categorizado em onze segmentos notáveis com base no tipo de produto, modo, tecnologia, modalidade, faixa etária, tipo de teste, abordagem, amostra, aplicação, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os principais segmentos de crescimento nas indústrias e a fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para tomar decisões estratégicas para identificar as principais aplicações do mercado.
Tipo de produto
- Instrumentos
- Consumíveis e Kits
- Outros
Com base no tipo de produto, o mercado está segmentado em consumíveis e kits, instrumentos, entre outros.
Modo
- Sem receita médica [OTC]
- Profissional
Com base na modalidade, o mercado está segmentado em profissional e de balcão [OTC].
Tecnologia
- Baseado em PCR
- Ensaios de fluxo
- Ensaios imunocromatográficos de fluxo lateral
- Microfluídica
- Tecnologia de Substrato
- Ensaio de Aglutinação
- Outros
Com base na tecnologia, o mercado está segmentado em ensaios baseados em PCR, fluxo, ensaios imunocromatográficos de fluxo lateral, ensaio de aglutinação, microfluídica, tecnologia de substrato, entre outros.
Modalidade
- Teste Baseado em Laboratório
- Teste não laboratorial
Com base na modalidade, o mercado está segmentado em testes laboratoriais e testes não laboratoriais.
Faixa etária
- Pediátrico
- Adulto
Com base na faixa etária, o mercado está segmentado em adulto e pediátrico.
Tipo de teste
- Determinando a confirmação
- Teste sorológico
- Sequenciamento Viral
Com base no tipo de teste, o mercado está segmentado em determinação de confirmação, testes serológicos e sequenciação viral.
Abordagem
- Diagnóstico Molecular
- Diagnóstico in vitro
Com base na abordagem, o mercado está segmentado em diagnóstico in vitro e diagnóstico molecular.
Amostra
- Cotonete
- Sangue
- Urina
- Saliva
- Escarro
- Outros
Com base na amostra, o mercado está segmentado em cotonetes, sangue, urina, saliva, expetoração, entre outros.
Aplicação
- Teste de doenças infeciosas
- Testes de Cardiologia
- Testes Oncológicos
- Teste de gravidez e fertilidade
- Testes toxicológicos
- Teste de drogas de abuso
- Teste Cardiometabólico
- Monitorização de Glicose
- Outros
Com base na aplicação, o mercado está segmentado em testes de doenças infeciosas, monitorização de glicose, testes cardiológicos, testes oncológicos, testes cardiometabólicos, testes de drogas de abuso, testes de gravidez e fertilidade, testes toxicológicos , entre outros.
Utilizador final
- Hospital e Clínica
- Laboratório de Diagnóstico
- Ambiente de atendimento domiciliário
- Institutos Académicos e de Investigação
- Outros
Com base no utilizador final, o mercado está segmentado em hospitais e clínicas, laboratórios de diagnóstico, ambientes de cuidados domiciliários, institutos de investigação e académicos, entre outros.
Canal de distribuição
- Concurso Direto
- Vendas no Retalho
Com base no canal de distribuição, o mercado está segmentado em concurso direto e vendas a retalho.
Análise Regional: Mercado Europeu de Testes de Diagnóstico Rápido (RDT)
O mercado europeu de testes de diagnóstico rápido (RDT) é analisado e são fornecidas informações sobre o tamanho do mercado: tipo de produto, modo, tecnologia, modalidade, faixa etária, tipo de teste, abordagem, amostra, aplicação, utilizador final e canal de distribuição.
Os países abrangidos no relatório de mercado da Europa Testes de Diagnóstico Rápido (RDT) são a Alemanha, França, Reino Unido, Itália, Espanha, Rússia, Turquia, Bélgica, Países Baixos, Suíça e resto da Europa.
Espera-se que a Alemanha domine o mercado devido à presença de grandes players do mercado e ao aumento dos avanços tecnológicos do teste de diagnóstico rápido da Europa na região.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade das marcas europeias e os desafios enfrentados devido à concorrência grande ou escassa das marcas locais e nacionais, o impacto dos canais de vendas são considerados, ao mesmo tempo que fornecem uma análise de previsão dos dados do país.
Mercado Europeu de Testes de Diagnóstico Rápido (RDT): Cenário Competitivo e Análise de Ações
O panorama competitivo do mercado europeu de testes de diagnóstico rápido (RDT) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto e respiração, domínio da aplicação, curva da linha de vida da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado europeu de testes de diagnóstico rápido.
As principais empresas que fornecem o mercado europeu de testes de diagnóstico rápido (RDT) são a Abbott, Danaher, Cellex, Fujirebio, Pharma, Access Bio, Cardinal Health, Bio-Rad Laboratories, Inc., BD, F. Hoffmann-La Roche Ltd , BIOMÉRIEUX SA , InBios International, Inc, Luminex Corporation. A DiaSorin Company, Gnomegen LLC, QIAGEN, Quidel Corporation, Sysmex Europe Gmbh (uma subsidiária da Sysmex Corporation), Cardinal Health, Siemens Healthcare Gmbh (uma subsidiária da Siemens Healthineers AG), MEGACOR DIAGNOSTIK GMBH, PerkinElmer Inc., Sekisui Diagnostics, PTS Diagnostics , werfen, Nova Biomedical e Trinity Biotech, entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE RAPID DIAGNOSTIC TESTS (RTD) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET APPLICATION COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASE IN INCIDENCE OF CHRONIC DISEASES
5.1.2 RISE IN GERIATRIC POPULATION OF THE INFECTIOUS DISEASES
5.1.3 TECHNOLOGICAL ADVANCEMENTS IN RAPID DIAGNOSTIC TESTING
5.1.4 GOVERNMENT INITIATIVES FOR DIAGNOSIS OF INFECTIOUS DISEASES
5.2 RESTRAINTS
5.2.1 HIGH COST ASSOCIATED WITH THE RAPID DIAGNOSTIC KITS
5.2.2 PRODUCT RECALLS IN RAPID DIAGNOSTIC TESTS
5.2.3 LACK OF AWARENESS ABOUT RAPID DIAGNOSTIC TESTING OF THE DISEASES
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATION AND PRODUCT LAUNCHES BY MARKET PLAYERS
5.3.2 RISE IN GOVERNMENT SUPPORT AND FUNDING FOR RAPID DIAGNOSTIC TEST
5.3.3 INCREASING AWARENESS ABOUT THE PROMPT AND EFFICIENT DIAGNOSIS
4.1 CHALLENGES
5.3.4 STRINGENT REGULATORY FOR MARKET APPROVAL
5.3.5 LACK OF TRAINING AND EXPERTISE IN THE DIAGNOSTIC CENTRES
6 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 CONSUMABLES AND KITS
6.2.1 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES
6.2.2 IMMUNOCHROMATOGRAPHIC ASSAY
6.2.2.1 ANTIBODY TESTS
6.2.2.1.1 TOTAL ANTIBODY ELISA KIT
6.2.2.1.2 IGM/IGG RAPID DIAGNOSTIC TEST
6.2.2.1.3 IGG ELISA KIT
6.2.2.1.4 IGM ELISA KIT
6.2.2.1.5 NEUTRALIZING ANTIBODY ELISA KIT
6.2.3 ANTIGEN ELISA KITS
6.2.4 SPECIMEN COLLECTION KIT
6.3 RT-PCR ASSAY KITS
6.3.1 REVERSE TRANSCRIPTION PCR (RT-PCR)
6.3.2 QUANTITATIVE REVERSE TRANSCRIPTION PCR (RT-QPCR)
6.3.3 OTHERS
6.4 INSTRUMENTS
6.4.1 PORTABLE
6.4.2 BENCHTOP
6.4.3 FIXED
6.5 OTHERS
7 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE
7.1 OVERVIEW
7.2 PROFESSIONAL
7.3 OVER-THE-COUNTER [OTC]
8 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 PCR-BASED
8.3 FLOW-THROUGH ASSAYS
8.4 LATERAL FLOW IMMUNOCHROMATOGRAPHIC ASSAYS
8.5 AGGLUTINATION ASSAY
8.6 MICROFLUIDICS
8.6.1 PAPER-BASED MICROFLUDICS
8.6.2 LUCIFERASE IMMUNOPRECIPITATION SYSTEMS (LIPS)
8.6.3 OTHERS
8.7 SUBSTRATE TECHNOLOGY
8.8 OTHERS
9 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY
9.1 OVERVIEW
9.2 LABORATORY BASED TEST
9.3 NON-LABORATORY BASED TEST
10 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 ADULT
10.3 PEDIATRIC
11 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE
11.1 OVERVIEW
11.2 DETERMINING CONFIRMATION
11.2.1 RT-PCR ASSAY KITS
11.2.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES
11.2.3 IMMUNOCHROMATOGRAPHIC ASSAY
11.2.4 OTHERS
11.3 SEROLOGICAL TESTING
11.3.1 RT-PCR ASSAY KITS
11.3.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES
11.3.3 IMMUNOCHROMATOGRAPHIC ASSAY
11.3.4 OTHERS
11.4 VIRAL SEQUENCING
11.4.1 RT-PCR ASSAY KITS
11.4.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES
11.4.3 IMMUNOCHROMATOGRAPHIC ASSAY
11.4.4 OTHERS
12 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH
12.1 OVERVIEW
12.2 IN-VITRO DIAGNOSTIC
12.3 MOLECULAR DIAGNOSTIC
13 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN
13.1 OVERVIEW
13.2 SWAB
13.3 BLOOD
13.4 URINE
13.5 SALIVA
13.6 SPUTUM
13.7 OTHERS
14 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 INFECTIOUS DISEASE TESTING
14.2.1 VIRUS
14.2.2 BACTERIA
14.2.3 OTHERS
14.3 GLUCOSE MONITORING
14.4 CARDIOLOGY TESTING
14.5 ONCOLOGY TESTING
14.5.1 LUNG CANCER
14.5.2 BREAST CANCER
14.5.3 BLOOD CANCER
14.5.4 OTHERS
14.6 CARDIOMETABOLIC TESTING
14.7 DRUGS-OF-ABUSE TESTING
14.8 PREGNANCY & FERTILITY TESTING
14.9 TOXICOLOGY TESTING
14.1 OTHERS
15 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL & CLINIC
15.3 DIAGNOSTIC LABORATORY
15.4 HOME CARE SETTING
15.5 RESEARCH AND ACADEMIC INSTITUTES
15.6 OTHERS
16 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
17 EUROPE BY COUNTRY
17.1 OVERVIEW
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 TURKEY
17.1.8 BELGIUM
17.1.9 NETHERLANDS
17.1.10 SWITZERLAND
17.1.11 REST OF EUROPE
18 EUROPE RAPID DIAGNOSTICS TESTS (RDT) MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILES
20.1 ABBOTT
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 F. HOFFMANN-LA ROCHE LTD
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG)
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 PTS DIAGNOSTICS
20.4.1 COMPANY SNAPSHOT
20.4.2 PRODUCT PORTFOLIO
20.4.3 RECENT DEVELOPMENTS
20.5 CARDINAL HEALTH
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ACCESS BIO
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENTS
20.7 BD
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 BIOMÉRIEUX SA
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 BIO-RAD LABORATORIES, INC.
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 CELLEX
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 DANAHER
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 FUJIREBIO (A SUBSIDIARY OF H.U. GROUP)
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
20.13 GNOMEGAN LLC
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 INBIOS INTERNATIONAL, INC
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 LUMINEX CORPORATION, A DIASORIN COMPANY
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 MEGAKOR DIAGNOSTIK GMBH
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
20.17 NOVA BIOMEDICAL
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 PERKIN ELMER INC.
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 QIAGEN
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 QUIDEL CORPORATION
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
20.21 SEKISUI DIAGNOSTICS
20.21.1 COMPANY SNAPSHOT
20.21.2 PRODUCT PORTFOLIO
20.21.3 RECENT DEVELOPMENTS
20.22 SYSMEX EUROPE GMBH (A SUBSIDIARY OF SYSMEX CORPORATION)
20.22.1 COMPANY SNAPSHOT
20.22.2 REVENUE ANALYSIS
20.22.3 PRODUCT PORTFOLIO
20.22.4 RECENT DEVELOPMENTS
20.23 TRINITY BIOTECH
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENT
20.24 WERFEN
20.24.1 COMPANY SNAPSHOT
20.24.2 PRODUCT PORTFOLIO
20.24.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tabela
TABLE 1 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 2 EUROPE CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 3 EUROPE IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 4 EUROPE ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 5 EUROPE RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 6 EUROPE INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 7 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 8 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 9 EUROPE MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 10 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 11 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 12 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 13 EUROPE DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 14 EUROPE SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 15 EUROPE VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 16 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 17 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 18 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 19 EUROPE INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 20 EUROPE ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 21 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 22 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 23 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 24 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 25 GERMANY CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 26 GERMANY IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 27 GERMANY ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 28 GERMANY RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 29 GERMANY INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 30 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 31 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 32 GERMANY MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 33 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 34 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 35 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 36 GERMANY DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 37 GERMANY SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 38 GERMANY VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 39 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 40 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 41 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 42 GERMANY INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 43 GERMANY ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 44 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 45 GERMANY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 47 FRANCE CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 48 FRANCE IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 49 FRANCE IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 50 FRANCE RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 51 FRANCE INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 52 FRANCE INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 53 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 54 FRANCE MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 55 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 56 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 57 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 58 FRANCE DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 59 FRANCE SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 60 FRANCE VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 61 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 62 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 63 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 64 FRANCE INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 65 FRANCE ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 66 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 67 FRANCE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 68 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 69 U.K. CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 70 U.K. IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 71 U.K. ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 72 U.K. RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 73 U.K. INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 74 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 75 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 76 U.K. MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 77 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 78 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 79 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 80 U.K. DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 81 U.K. SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.K. VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 83 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 84 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 85 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 86 U.K. INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 87 U.K. ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 88 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 89 U.K. RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 90 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 91 ITALY CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 92 ITALY IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 93 ITALY ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 94 ITALY RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 95 ITALY INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 96 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 97 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 98 ITALY MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 99 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 100 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 101 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 102 ITALY DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 103 ITALY SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 104 ITALY VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 105 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 106 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 107 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 108 ITALY INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 109 ITALY ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 110 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 ITALY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 112 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 113 SPAIN CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 114 SPAIN IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 115 SPAIN ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 116 SPAIN RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 117 SPAIN INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 118 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 119 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 120 SPAIN MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 121 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 122 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 123 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 124 SPAIN DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 125 SPAIN SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 126 SPAIN VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 127 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 128 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 129 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 130 SPAIN INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 131 SPAIN ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 132 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 133 SPAIN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 134 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 135 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 136 RUSSIA IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 137 RUSSIA ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 138 RUSSIA RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 139 RUSSIA INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 140 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 141 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 142 RUSSIA MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 143 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 144 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 145 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 146 RUSSIA DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 147 RUSSIA SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 148 RUSSIA VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 149 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 150 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 151 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 152 RUSSIA INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 153 RUSSIA ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 154 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 155 RUSSIA RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 156 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 157 TURKEY CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 158 TURKEY IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 159 TURKEY ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 160 TURKEY RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 161 TURKEY INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 162 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 163 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 164 TURKEY MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 165 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 166 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 167 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 168 TURKEY DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 169 TURKEY SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 170 TURKEY VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 171 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 172 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 173 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 174 TURKEY INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 175 TURKEY ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 176 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 177 TURKEY RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 178 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 179 BELGIUM CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 180 BELGIUM IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 181 BELGIUM ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 182 BELGIUM RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 183 BELGIUM INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 184 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 185 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 186 BELGIUM MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 187 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 188 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 189 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 190 BELGIUM DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 191 BELGIUM SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 192 BELGIUM VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 193 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROCH, 2022-2031 (USD MILLION)
TABLE 194 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 195 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 196 BELGIUM INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 197 BELGIUM ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 198 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 199 BELGIUM RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 201 NETHERLANDS CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 202 NETHERLANDS IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 203 NETHERLANDS ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 204 NETHERLANDS RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 205 NETHERLANDS INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 206 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 207 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 208 NETHERLANDS MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 209 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 210 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 211 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 212 NETHERLANDS DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 213 NETHERLANDS SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 214 NETHERLANDS VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 215 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROCH, 2022-2031 (USD MILLION)
TABLE 216 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 217 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 218 NETHERLANDS INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 219 NETHERLANDS ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 220 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 221 NETHERLANDS RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 222 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 223 SWITZERLAND CONSUMABLES AND KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 224 SWITZERLAND IMMUNOCHROMATOGRAPHIC ASSAY IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 225 SWITZERLAND ANTIBODY TESTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 226 SWITZERLAND RT-PCR ASSAY KITS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 227 SWITZERLAND INSTRUMENTS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 228 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE, 2022-2031 (USD MILLION)
TABLE 229 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 230 SWITZERLAND MICROFLUIDICS IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 231 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY, 2022-2031 (USD MILLION)
TABLE 232 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 233 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 234 SWITZERLAND DETERMINING CONFIRMATION IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 235 SWITZERLAND SEROLOGICAL TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 236 SWITZERLAND VIRAL SEQUENCING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)
TABLE 237 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH, 2022-2031 (USD MILLION)
TABLE 238 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN, 2022-2031 (USD MILLION)
TABLE 239 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 240 SWITZERLAND INFECTIOUS DISEASE TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 241 SWITZERLAND ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 242 SWITZERLAND ONCOLOGY TESTING IN RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 243 SWITZERLAND RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 244 REST OF EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
Lista de Figura
FIGURE 1 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SEGMENTATION
FIGURE 2 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE RAPID DIAGNOSTIC TESTS (RTD) MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: APPLICATION COVERAGE GRID
FIGURE 10 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SEGMENTATION
FIGURE 11 THE INCREASED BURDEN OF INFECTIOUS DISEASES, RISE IN AWARENESS OF RAPID DIAGNOSTIC TESTS, AND RISE IN PRODUCT LAUNCHES ARE DRIVING THE GROWTH OF THE EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET FROM 2024 TO 2031
FIGURE 12 CONSUMABLES AND KITS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET FROM 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE RAPID DIAGNOSTIC TESTS (RTD) MARKET
FIGURE 14 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY PRODUCT TYPE, 2023
FIGURE 15 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)
FIGURE 16 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 17 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODE, 2023
FIGURE 19 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODE, 2024-2031 (USD MILLION)
FIGURE 20 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODE, CAGR (2024-2031)
FIGURE 21 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODE, LIFELINE CURVE
FIGURE 22 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TECHNOLOGY, 2023
FIGURE 23 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 24 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TECHNOLOGY, CAGR (2024-2031)
FIGURE 25 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODALITY, 2023
FIGURE 27 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODALITY, 2024-2031 (USD MILLION)
FIGURE 28 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODALITY, CAGR (2024-2031)
FIGURE 29 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY MODALITY, LIFELINE CURVE
FIGURE 30 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY AGE GROUP, 2023
FIGURE 31 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)
FIGURE 32 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 33 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 34 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TEST TYPE, 2023
FIGURE 35 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TEST TYPE, 2024-2031 (USD MILLION)
FIGURE 36 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TEST TYPE, CAGR (2024-2031)
FIGURE 37 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 38 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY APPROACH, 2023
FIGURE 39 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY APPROACH, 2024-2031 (USD MILLION)
FIGURE 40 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY APPROACH, CAGR (2024-2031)
FIGURE 41 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY APPROACH, LIFELINE CURVE
FIGURE 42 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY SPECIMEN, 2023
FIGURE 43 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY SPECIMEN, 2024-2031 (USD MILLION)
FIGURE 44 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY SPECIMEN, CAGR (2024-2031)
FIGURE 45 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY SPECIMEN, LIFELINE CURVE
FIGURE 46 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY APPLICATION, 2023
FIGURE 47 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 48 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 49 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 50 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY END USER, 2023
FIGURE 51 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 52 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 53 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 54 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 55 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 56 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 57 EUROPE RAPID DIAGNOSTIC TESTS (RDT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 58 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SNAPSHOT (2023)
FIGURE 59 EUROPE RAPID DIAGNOSTICS TESTS (RDT) MARKET: COMPANY SHARE 2023 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
